[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Contineum Therapeutics Inc (CTNM)

Contineum Therapeutics Inc (CTNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 648,962
  • Shares Outstanding, K 37,621
  • Annual Sales, $ 0 K
  • Annual Income, $ -59,980 K
  • EBIT $ -66 M
  • EBITDA $ -66 M
  • 60-Month Beta 0.74
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.67

Options Overview Details

View History
  • Implied Volatility 124.27% (+87.04%)
  • Historical Volatility 61.16%
  • IV Percentile 3%
  • IV Rank 27.11%
  • IV High 358.30% on 12/09/25
  • IV Low 37.23% on 08/26/26
  • Expected Move (DTE 21) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.25
  • Today's Volume 18
  • Volume Avg (30-Day) 255
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 3,645
  • Open Int (30-Day) 2,695
  • Expected Range 17.05 to 17.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.45
  • Number of Estimates 3
  • High Estimate $-0.40
  • Low Estimate $-0.51
  • Prior Year $-0.45
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.90 +22.66%
on 07/29/26
17.51 -2.63%
on 08/25/26
+2.89 (+20.41%)
since 07/28/26
3-Month
11.17 +52.64%
on 06/10/26
17.51 -2.63%
on 08/25/26
+3.74 (+28.10%)
since 05/28/26
52-Week
8.60 +98.26%
on 01/08/26
17.51 -2.63%
on 08/25/26
+7.00 (+69.65%)
since 08/28/25

Most Recent Stories

More News
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases...

CTNM : 17.05 (-1.16%)
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases...

CTNM : 17.05 (-1.16%)
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) - Blocking...

CTNM : 17.05 (-1.16%)
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 17.05 (-1.16%)
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential

Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory...

CTNM : 17.05 (-1.16%)
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 17.05 (-1.16%)
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 17.05 (-1.16%)
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 17.05 (-1.16%)
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 17.05 (-1.16%)
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 17.05 (-1.16%)

Business Summary

Contineum Therapeutics Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies which target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications...

See More

Key Turning Points

3rd Resistance Point 17.79
2nd Resistance Point 17.60
1st Resistance Point 17.32
Last Price 17.05
1st Support Level 16.85
2nd Support Level 16.66
3rd Support Level 16.38

See More

52-Week High 17.51
Last Price 17.05
Fibonacci 61.8% 14.11
Fibonacci 50% 13.06
Fibonacci 38.2% 12.00
52-Week Low 8.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.